Who are Nuvalent, Inc.'s main suppliers?

Nuvalent, Inc. (NUVL) key suppliers include: CMOS, CROS, Royalty Pharma plc, Royalty Pharma plc. View the full supplier network at chainsifter.com/chain/NUVL.

Who are Nuvalent, Inc.'s major customers?

Nuvalent, Inc. (NUVL) key customers include: DEERFIELD, Royalty Pharma plc, Royalty Pharma plc, Merck & Co., Inc., Merck & Co., Inc. and 5 more. View the full customer network at chainsifter.com/chain/NUVL.

What sector is Nuvalent, Inc. in?

Nuvalent, Inc. (NUVL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

NUVL Supply Chain: Nuvalent, Inc. Supplier List & 15 Relationships

4Suppliers

10Customers

1Debt Items

20Related Chains

Nuvalent, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CMOS	CMOS	92%	drug substance and finished drug product manufacturing to CMOs
CROS	CROS	92%	Currently, we outsource substantially all clinical trial work to CROs
RPRX	Royalty Pharma plc	72%	d other current assets of $16.9 million. During the year ended December 31, 2024, operating activities used $185.1 million of cash, resulting from our net loss of $260.8 million adjusted for non-cash…
RPRX	Royalty Pharma plc	72%	Reciprocal relationship from RPRX graph: Reciprocal relationship from NUVL graph: d other current assets of $16.9 million. During the year ended December 31, 2024, operating activities used $185.1 mi…

Nuvalent, Inc. Customers

Ticker	Name	Confidence	Evidence
DEERFIELD	DEERFIELD	90%	The Company has a revenue sharing agreement with Deerfield pursuant to which the Company is obligated to pay Deerfield a fixed low single-digit percentage rate of net sales of certain commercial products
RPRX	Royalty Pharma plc	90%	lue of the related party revenue share liability was $55.2 million and $17.9 million for the years ended December 31, 2025 and 2024, respectively. For the years ended December 31, 2025 and 2024, the …
RPRX	Royalty Pharma plc	90%	Reciprocal relationship from RPRX graph: Reciprocal relationship from NUVL graph: lue of the related party revenue share liability was $55.2 million and $17.9 million for the years ended December 31,…
MRK	Merck & Co., Inc.	72%	rers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are required to comply with the applicable p…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from NUVL graph: rers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing …
BOEHRINGER-INGELHEIM-PHARMACEUTICALS-INC	BOEHRINGER-INGELHEIM-PHARMACEUTICALS-INC	62%	. We have never commercialized a product candidate as a company. We may license certain rights with respect to our product candidates to collaborators, and, if so, we will rely on the assistance and …
COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY	COMMERCE-BRISTOL-MYERS-SQUIBB-COMPANY	62%	rers must also establish registration and device listings with the FDA. A medical device manufacturer’s manufacturing processes and those of its suppliers are required to comply with the applicable p…
COMPANY-LLC	COMPANY-LLC	62%	ompensation expense was $29.2 million and $14.0 million, respectively. Other income (expense) Change in fair value of related party revenue share liability The change in fair value of the related par…
NUVATION-BIO-INC	NUVATION-BIO-INC	62%	. We have never commercialized a product candidate as a company. We may license certain rights with respect to our product candidates to collaborators, and, if so, we will rely on the assistance and …
SHANGHAI-HENGRUI-PHARMACEUTICAL-CO-LTD	SHANGHAI-HENGRUI-PHARMACEUTICAL-CO-LTD	62%	. We have never commercialized a product candidate as a company. We may license certain rights with respect to our product candidates to collaborators, and, if so, we will rely on the assistance and …

Nuvalent, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
NUVL-DEBT-11417	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

Nuvalent, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Nuvalent, Inc..

Nuvalent, Inc. Ownership

Holder	Name	Confidence	Evidence
NUVL-OWNER-DEERFIELD-MANAGEMENT-COMPANY-L-P	DEERFIELD MANAGEMENT COMPANY, L.P.	90%	13F overlay lists DEERFIELD MANAGEMENT COMPANY, L.P. as top holder; 266 tracked holders.

Nuvalent, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
IBIO	iBio, Inc.	100.00	2
MCUJF	Medicure Inc.	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
SWKH	SWK Holdings Corp	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
ENLV	Enlivex Ltd.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
BNBX	BNB Plus Corp.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
EVAX	Evaxion A/S	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
MGNX	MacroGenics, Inc.	100.00	2

Nuvalent, Inc. Supply Chain